Tbe vaccin katt

TBE vaccine. One tick-borne encephalitis vaccine (called TICOVAC) is available in the United States. TICOVAC is given as a 3-dose series: Adults 16 years of age and older should have the first two doses spaced 14 days to 3 months apart and the third dose 5–12 months after the second dose. One inactivated tick-borne encephalitis (TBE) vaccine (manufactured as TICOVAC) is available in the United States.

TBE vaccine is approved for persons 1 year of age and older. TBE is a very low risk disease for most travelers. TBE vaccine is recommended for many laboratory workers who might be exposed to the TBE virus. TBE vaccine is given as three-dose primary series. People 1 through 15 years of age get a smaller dose ( mL) than people 16 years and older ( mL).

In the United States, tick-borne encephalitis vaccine is indicated for active immunization to prevent tick-borne encephalitis (TBE) in individuals one year of age and older. [2] The efficacy of these vaccines has been well documented. [4]. Tick-borne encephalitis vaccine can prevent tickborne encephalitis. Tick-borne encephalitis, or TBE, is caused by a virus that is spread through the bite of an infected tick.

TBE virus can be found in parts of Europe and Asia. TBE virus is not found in the United States. Immunization offers the most effective protection against tick-borne encephalitis. Currently, there are four widely used vaccines of assured quality: FSME-Immun and Encepur, manufactured in Austria and Germany respectively, and TBE-Moscow and EnceVir, manufactured in the Russian Federation.

On Aug. 13, , the Food and Drug Administration approved a TBE vaccine (manufactured by Pfizer as TICOVAC) for use in persons aged ≥1 year. The vaccine is inactivated with a vaccination schedule of three primary doses, and one booster dose administered at ≥3 years after the primary series if there is ongoing risk of exposure.